about
A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis.Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury.Combining GP73 with liver stiffness measurements: A proof-of-concept for non-invasive fibrosis assessment in antiviral-naïve HBV patients.Growth Differentiation Factor-15 Is a Predictor of Mortality in Critically Ill Patients with Sepsis.A not so easy genotype-striking regional differences in SOF/RBV treatment responses in HCV GT2.Elevated Serum Levels of Mixed Lineage Kinase Domain-Like Protein Predict Survival of Patients during Intensive Care Unit Treatment.Machine perfusion for liver transplantation in the era of marginal organs-New kids on the blockCirculating Levels of Osteopontin Predict Patients' Outcome after Resection of Colorectal Liver MetastasesVisfatin Serum Levels Predict Mortality in Critically Ill PatientsRelevance of Autophagy in Parenchymal and Non-Parenchymal Liver Cells for Health and DiseaseHigh Circulating Caspase-Cleaved Keratin 18 Fragments (M30) Indicate Short-Term Mortality in Critically Ill PatientsClinical relevance of copeptin plasma levels as a biomarker of disease severity and mortality in critically ill patientsHigh mobility group box 1 as a biomarker in critically ill patientsNeutrophils are a main source of circulating suPAR predicting outcome in critical illnessPrognostic Relevance of Altered Lymphocyte Subpopulations in Critical Illness and SepsismiR-155 Predicts Long-Term Mortality in Critically Ill Patients Younger than 65 YearsLiver Macrophages: Old Dogmas and New Insights.Serum Levels of miR-143 Predict Survival in Critically Ill PatientsSerum Levels of Kisspeptin Are Elevated in Patients with Pancreatic CancerPrimary Neuroendocrine Neoplasms of the Breast: Case Series and Literature ReviewIschemia-Reperfusion Injury in Marginal Liver Grafts and the Role of Hypothermic Machine Perfusion: Molecular Mechanisms and Clinical ImplicationsNew drugs for NAFLD: lessons from basic models to the clinicReport on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLDThe role of the innate immune system in the development and treatment of hepatocellular carcinomaElevated MR-proANP plasma concentrations are associated with sepsis and predict mortality in critically ill patientsMyeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitisSerum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosisSingle Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver FibrosisCenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR StudyErratum: Hohlstein, P. et al. Prognostic Relevance of Altered Lymphocyte Subpopulations in Critical Illness and Sepsis. Journal of Clinical Medicine 2019, 8, 353Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAsThe Unexpected Role of Neutrophils for Resolving Liver Inflammation by Transmitting MicroRNA-223 to MacrophagesResponse to the "Letter to the editor regarding article, 'High-mobility group box 1 as a biomarker in critically ill patients'."High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLDRecent Advances and the Potential for Clinical Use of Autofluorescence Detection of Extra-Ophthalmic TissuesSoluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations are Elevated in Patients with Neuroendocrine MalignanciesHow effective are nonalcoholic fatty liver disease models for drug discovery?
P50
Q40082820-8DFE0EF8-67CE-4D8B-B269-47D2BA652DA3Q41071492-220D471B-7C29-4D99-A01D-4D1F47B594A8Q45873545-69DBAA27-0069-4ED0-99CA-A70B29960BDCQ47213170-2777EE56-E9B5-4513-8BE7-46CF3185A6F9Q48121008-E9E7C28D-1D6B-4638-8C0A-A2F2792E146BQ52722360-1FFAD467-A45D-481B-8C12-05DF5EC7133CQ57168518-814995FF-0546-4529-869B-B7F9F75717CCQ58114800-45A77D00-4A1E-470A-BEAE-FAA2951297CFQ58702208-B8E6A4CB-4D7E-40AD-9B0D-1DECB7E9E896Q61808705-70592213-9661-4331-903D-3AD19EB3C2FDQ62734445-1D074E78-213F-4ADD-BA4B-6FDAD61F7D2BQ62734448-0CE4FDCD-1392-47BB-8185-91ADFC7A44E2Q62734453-17BA6A5E-3CD1-4B51-90F9-66834BF6851DQ64083855-A4C3DB51-BBE8-412B-9203-CBA5BC2BFE06Q64103588-D14E7267-ADFA-4B9D-B214-F4C11909694BQ64107795-2E80E316-8629-4595-8E0B-300CFD43E801Q64946007-7F2977E0-C1FC-4AFE-99B9-419740FEC0E2Q91476757-4C06E430-3FF2-4C74-A34B-5E8FB56E3B99Q91476785-4D37C39D-4F21-4F7E-9335-86245283B4B4Q91546621-95F27FE7-9336-4FD5-9371-FDAF54F0A13EQ91546903-01F9BD1D-E5BA-4E9A-ACA5-574094EFA092Q91701142-8C3B2A4E-E31C-4120-A548-2E99940DB3F3Q91740556-6EF7F013-DBA7-4EB9-8607-BCA62E0E27C7Q91791487-537FD547-D774-4B82-8437-6759923398DDQ91925291-B1C2825F-A01C-4035-A65A-3AC43EF64271Q91928674-BDA004E3-CD6F-472F-91F1-CA323F4F469AQ92016253-A26EE7AA-D681-4FA6-9FF3-88CAA5BFF6F7Q92350106-C6D37D49-2DCF-49F4-8AC3-E84BF5D74642Q92676614-07FC605B-3587-429D-9ECD-5DBBE855B011Q92876762-DBB3173F-EAE0-43C2-A0ED-9302BA814886Q93043263-3D461CC0-21CD-4B32-8875-081CBC29028BQ93099839-EF0307E3-1CE6-4896-B5ED-D0C730010A7EQ93358401-3AAE03CF-EAFC-4E92-9729-256627D29E80Q94503839-4D07295E-1DF6-42F0-B9F6-B88E06D37E2FQ94515552-5973CF1D-DD64-4F6D-A62C-21B294584D3FQ96117525-B2DE64AF-A919-4B67-A00A-6EBBB6B0AE9FQ96308489-4414EF2E-8AFF-42F5-8BC6-CCA5936405FD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Frank Tacke
@ast
Frank Tacke
@en
Frank Tacke
@es
Frank Tacke
@nl
type
label
Frank Tacke
@ast
Frank Tacke
@en
Frank Tacke
@es
Frank Tacke
@nl
prefLabel
Frank Tacke
@ast
Frank Tacke
@en
Frank Tacke
@es
Frank Tacke
@nl
P106
P21
P31
P496
0000-0001-6206-0226